Executive Summary
Five significant contract modifications totaling $1.33B in obligations highlight sustained federal demand in health services (52% HHS allocation via Carahsoft and Leidos), with four bullish signals driven by long-term commitments to 2027-2029 and massive option upside exceeding $5B combined. Neutral signal on nonprofit Family Endeavors reflects full $347M outlay but limited scalability.
Investors should prioritize Leidos, Carahsoft for revenue visibility amid firm fixed price risks and low outlays in select contracts like Idemia.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Significant Contract Modifications ($10M+) digest from March 28, 2026.
Investment Signals (4)
- HHS long-term health contracts fully committed (HIGH)▲
Carahsoft ($465M) and Leidos ($234M) secure HHS obligations with $337M and $157M outlayed, extending to 2028-2029 for software verification and COVID R&D.
- $5B+ options upside across contracts (MEDIUM)▲
Options expand values to $2.1B (Carahsoft), $3.3B (Family Endeavors), and smaller adds for others, signaling potential 4x growth beyond $1.33B obligations.
- Stable revenue in security and finance services (HIGH)▲
Idemia ($204M to 2027) and NISA ($84M to 2027) provide decade-long commitments in passports and pension investments, with $44M outlayed for NISA.
- Nonprofit facilities support fully funded short-term (HIGH)▲
Family Endeavors' $347M DOI obligation fully outlayed for 2-year influx care, but nonprofit status caps investor appeal despite $3.3B options.
Risk Flags (3)
- Execution [HIGH RISK]▼
Firm fixed price in 60% of contracts (Carahsoft, Idemia, NISA) risks margin squeeze if costs rise; Idemia shows $0 outlay despite 9-year history.
- Market [MEDIUM RISK]▼
Long horizons to 2029 expose all to budget shifts; options ($5B+ potential) not guaranteed beyond base obligations.
- Competitive [MEDIUM RISK]▼
Full/open competition in most, but Family Endeavors' exclusion of sources and nonprofit status may hinder scalability.
Opportunities (3)
- ◆
Exercise $5B+ options, especially Carahsoft ($1.6B) and Family Endeavors ($3B), plus $128M/$77M/$40M remaining outlays.
- ◆
HHS focus (52% value) in software/R&D signals multi-year health tech expansion to 2029.
- ◆
Idemia/NISA long-term deals with low outlays offer upside as funding ramps to 2027.
Sector Themes (3)
- ◆
52% of $1.33B in HHS contracts for verification software and COVID R&D, with full obligations to 2029.
- ◆
All contracts span 2-10 years to 2027-2029, blending FFP/T&M/CPFF pricing.
- ◆
Base obligations dwarfed by $5B+ options, concentrated in facilities/health.
Watch List (3)
- 👁
{"entity"=>"Carahsoft Technology Corp", "reason"=>"Largest obligation ($465M) with $2B ceiling in CMS software.", "trigger"=>"Option exercises or outlay >$400M"}
- 👁
{"entity"=>"Idemia National Security Solutions LLC", "reason"=>"$204M State Dept with $0 outlay signals execution ramp needed.", "trigger"=>"Outlay commencement or delays"}
- 👁
{"entity"=>"Family Endeavors Inc options ($3.3B)", "reason"=>"Massive upside despite neutral nonprofit signal and short base term.", "trigger"=>"Extension beyond 2025 or option awards"}
Get daily alerts with 4 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 5 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Significant Contract Modifications ($10M+)
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals